Independent regulators have recommended the continuation of the Ovature ovarian cancer trial, being run by Novogen's (ASX: NRT) subsidiary Marshall Edwards.

The trial's Independent Data Monitoring Committee (IDMC) recommended the continuation of the phase III trial of the orally administered investigational drug phenoxodiol, a chemosensitising agent, in women with advanced, refractory ovarian cancer.

The trial is being run to determine its safety and effectiveness when used in combination with carboplatin.

The trial has been approved by the US FDA under a special protocol assessment program. It is recruiting patients in clinical sites across the US, UK, Europe and Australia.